Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-05231023

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antibodies, Monoclonal, HumanizedFibroblast Growth Factor

Narrower (1)

CVX-343

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing
Pharmacological administration of FGF21 analogues has shown robust body weight reduction and lipid profile improvement in both… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with…
AIMS To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting fibroblast growth… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
Review
2017
Review
2017
FGF21 and metabolic disease in 2016: A new frontier in FGF21 biology
In 2016, four studies were published that provided crucial new information on the endocrine actions of the hormone fibroblast… Expand
  • figure 1
Is this relevant?
2017
2017
Once-weekly administration of a long-acting FGF 21 analogue modulates lipids , bone turnover markers , blood pressure , and body weight differently in obese hypertriglyceridemic subjects and in non…
 
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
FGF21 plays a central role in energy, lipid, and glucose homeostasis. To characterize the pharmacologic effects of FGF21, we… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2015
2015
Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
AIMS The aim of the present study was to evaluate the pharmacokinetics/pharmacodynamics (PK/PD), safety and tolerability of… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2015
2015
Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
Pharmacological administration of fibroblast growth factor 21 (FGF21) improves metabolic profile in preclinical species and… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Protein Conjugate
PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, was generated by covalently conjugating two engineered… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE